Yonghui Wang

Dr. Yonghui Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
DCDaxia Cai
Daxia Cai
FTFeng Tian
Feng Tian
MWMinhua Wu
Minhua Wu
JTJianfei Tu
Jianfei Tu
YWYonghui Wang
Yonghui Wang
The mechanism of action of UBE2C in lung adenocarcinoma (LUAD) and its significance in cancer diagnosis, targeted therapy and immunotherapy, even in pan-cancer, are still unclear. Several large public databases and online analysis tools were used for big data mining analysis. RNA interference technology, CCK8 assay, flow cytometry and apoptosis detection, and western blot were used for in vitro experiments. UBE2C was found to be overexpressed in various of tumors, including LUAD, and its expression level was found to be significantly related to gender, weight, tumor stage, grade and prognosis in LUAD. Downregulation of UBE2C expression induced proliferation suppression and G2/M phase arrest and cell apoptosis in LUAD cells and suppressed LUAD cell growth through inhibiting the Akt-mTOR signaling pathway. Expression level of UBE2C was negatively correlated with B cells and CD4+ T cell, and also with immune checkpoint genes in LUAD. Pan-cancer assay shown that UBE2C was significantly overexpressed in 28 cancers and was correlated with Ki-67 index in many cancers. Overexpression of UBE2C in BRCA, LUAD and MESO indicated worse Overall Survival (OS). UBE2C expression levels were positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI and MMRs in some cancers. Additionally, Single-cell functional analysis showed that UBE2C was positively correlated with cell cycle, proliferation, DNA damage, EMT, DNA repair, invasion and differentiation in some cancers. These findings suggested that UBE2C could be regarded as a latent diagnosis and prognostic biomarker and a new target for immunological therapy of cancers including LUAD.

3 February 2025 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
DCDa Xia Cai
Da Xia Cai
FTFeng Tian
Feng Tian
DZDeng Ke Zhang
Deng Ke Zhang
JTJianfei Tu
Jianfei Tu
YWYonghui Wang
Yonghui Wang
Objective: Overexpressed CRABP2 (Cellula Retinoi Aci Bindin Protei 2D) can promote progression of various tumors. However, there are few comprehensive analysis studies on CRABP2 in lung adenocarcinoma (LUAD).


1 March 2025 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
YZYanyan Zhu
Yanyan Zhu
DCDaxia Cai
Daxia Cai
JJJiangle Jiang
Jiangle Jiang
JTJianfei Tu
Jianfei Tu
ZTZhifeng Tian
Zhifeng Tian
YWYonghui Wang
Yonghui Wang
Penile cancer is a rare malignant tumor with a poor prognosis in advanced stages. Immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy in patients with advanced penile cancer, but it can also induce immune-related adverse events (irAEs). This article reports a patient who achieved almost a complete response to the PD-1 inhibitor sintilimab as third-line treatment for advanced penile squamous cell cancer with massive ulceration of chemoradiotherapy-resistant, and successful treatment by immunotherapy. One year into maintenance therapy with sintilimab, skin toxicity in the form or grade-2 skin rashes and grade-3 pruritus occurred. Sintilimab was permanently discontinued. The skin toxicity was effectively controlled by oral prednisone at a daily dosage of 15 mg. At the last follow-up of 16 months after sintilimab discontinuation, the patient remained in partial response, with total progression-free survival exceeding 30 months. We also conducted a comprehensive literature search, and summarized skin toxicity of ICIs administration. These articles suggested that immune-related skin toxicity may be indicative of good treatment response.

18 June 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DCDaxia Cai
Daxia Cai
JLJun Li
Jun Li
QCQiyi Chen
Qiyi Chen
XCXingdong Cai
Xingdong Cai
FTFeng Tian
Feng Tian
YWYonghui Wang
Yonghui Wang
Pulmonary sarcomatoid carcinoma (PSC) is frequently underdiagnosed or misdiagnosed due to its rarity and complex histological features. To date, no universally recommended treatment regimens have been established for this rare subtype, and clinical management is currently extrapolated primarily from standard non-small cell lung cancer (NSCLC) protocols. Herein, we report a case of PSC initially diagnosed as multiple primary lung cancer, including adenosquamous carcinoma and adenocarcinoma (pT1N0M0, IA stage, EGFR Exon-21 L858R mutation, below the detection limit) and adenocarcinoma (pT2aN0M0, stage IB, EGFR Exon-21 L858R mutation). Despite radical surgical resection followed by targeted therapy with afatinib (30 mg orally once daily), the disease recurred. Repeat biopsy confirmed the diagnosis of PSC secondary to histological transformation. The patient achieved a durable complete response (CR) to combined immunochemotherapy. We further review the existing literature on EGFR-TKI-associated histological transformation in lung cancer, to provide guidance for the clinical management of this challenging clinical scenario.

18 February 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DCDaxia Cai
Daxia Cai
JLJian Lou
Jian Lou
YZYanyan Zhu
Yanyan Zhu
YWYonghui Wang
Yonghui Wang
Background: Germ-line EGFR mutations are rare, and their clinical significance, particularly regarding response to tyrosine kinase inhibitors (TKIs), remains poorly defined. The EGFR V831H (also known as R831H) mutation is an exceptionally rare variant with constitutive activity, and data on its therapeutic sensitivity are scarce. Methods: We present a detailed case report of a patient with advanced non-small cell lung cancer (NSCLC) harboring a germ-line EGFR V831H mutation. Diagnosis involved imaging, histopathology, and comprehensive genomic profiling of tumor tissue. Germ-line origin was confirmed via Sanger sequencing of normal patient tissue and a familial sample. Case presentation: A 68-year-old man was diagnosed with stage IIIB lung adenocarcinoma and concurrent latent tuberculosis infection (LTBI). Next-generation sequencing of a lymph node biopsy revealed co-occurring somatic KRAS G12V and an EGFR exon 21 V831H mutation, which was subsequently identified as a germ-line variant. The patient initiated antituberculosis therapy (rifampicin and isoniazid) followed by the third-generation EGFR-TKI almonertinib (110 mg/day). Results: The disease demonstrated primary resistance to almonertinib, with radiological progression in thoracic lymph nodes observed within 20 days of treatment initiation. The patient died one month later with evidence of new brain metastases. Conclusion: This case highlights primary resistance to the third-generation EGFR-TKI almonertinib in a patient with NSCLC harboring a germ-line EGFR V831H mutation. The rapid progression suggests that this specific germ-line variant may confer inherent TKI resistance, potentially exacerbated by the presence of a concurrent KRAS G12V mutation and drug-drug interactions between almonertinib and antituberculosis medications. It underscores the clinical challenge of germ-line EGFR mutations and emphasizes the need for further research to establish effective therapeutic strategies for such rare genotypes.